Difference between revisions of "Epratuzumab (LymphoCide)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
Warner-admin (talk | contribs) |
||
Line 7: | Line 7: | ||
==Also known as== | ==Also known as== | ||
− | *'''Code name:''' AMG 412 | + | *'''Code name:''' AMG 412, hLL2 |
*'''Brand name:''' LymphoCide | *'''Brand name:''' LymphoCide | ||
Line 13: | Line 13: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
− | |||
− | |||
[[Category:Anti-CD22 antibodies]] | [[Category:Anti-CD22 antibodies]] |
Revision as of 01:28, 29 February 2020
Mechanism of action
Anti-CD22 antibody
Preliminary data
Acute lymphocytic leukemia
- SWOG S0910: Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. PubMed link to original article
Also known as
- Code name: AMG 412, hLL2
- Brand name: LymphoCide